lenalidomide has been researched along with triazoles in 13 studies
| Studies (lenalidomide) | Trials (lenalidomide) | Recent Studies (post-2010) (lenalidomide) | Studies (triazoles) | Trials (triazoles) | Recent Studies (post-2010) (triazoles) |
|---|---|---|---|---|---|
| 3,532 | 725 | 2,850 | 25,808 | 2,252 | 13,501 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (23.08) | 29.6817 |
| 2010's | 9 (69.23) | 24.3611 |
| 2020's | 1 (7.69) | 2.80 |
| Authors | Studies |
|---|---|
| Steensma, DP; Tefferi, A | 1 |
| Ozawa, K | 1 |
| Ohyashiki, K | 1 |
| Tefferi, A | 1 |
| Miyazaki, Y | 1 |
| Alimena, G; Breccia, M; Colafigli, G; Federico, V; Finsinger, P; Latagliata, R; Loglisci, G; Petrucci, L; Salaroli, A; Santopietro, M; Serrao, A | 1 |
| Cuzzola, M; Gentile, M; Morabito, F; Morabito, L; Recchia, AG; Vigna, E | 1 |
| Tohyama, K | 1 |
| Chaudhary, PM; Gopalakrishnan, R; Matta, H; Tolani, B; Triche, T | 1 |
| Akuffo, AA; Alontaga, AY; Ayaz, M; Beatty, MS; Becker, A; Daniel, K; Epling-Burnette, PK; Goodheart, WE; Guida, W; Gunawan, S; Hesterberg, RS; Karim, MR; Lawrence, HR; Lawrence, NJ; McDaniel, JM; Metcalf, R; Orobello, ME; Rajadhyaksha, AM; Schönbrunn, E; Yang, Y; Yoder, JA | 1 |
| Aoufouchi, S; Armand, M; Azar, N; Bernard, OA; Camara-Clayette, V; Charbonnier, JB; Charlotte, F; Cornillet-Lefebvre, P; Cosset, FL; Damm, F; Decaudin, C; Della-Valle, V; Dessen, P; Diop, MK; Droin, N; Durot, E; Elemento, O; Ghamlouch, H; Guillouf, C; Haddad, R; Hérate, C; Lara, D; Leblond, V; Mercher, T; Metzner, M; Morel, P; Mylonas, E; Nguyen-Khac, F; Pflumio, F; Rameau, P; Ribrag, V; Roos-Weil, D; Ropars, V; Stoilova, B; Verhoeyen, E; Vyas, P | 1 |
| Estey, EH; Percival, MM | 1 |
| Harris, LJ; Martin, M; Patel, K | 1 |
7 review(s) available for lenalidomide and triazoles
| Article | Year |
|---|---|
Risk-based management of myelodysplastic syndrome.
Topics: Anemia, Sideroblastic; Antilymphocyte Serum; Azacitidine; Benzoates; Decitabine; Deferasirox; DNA Modification Methylases; Enzyme Inhibitors; Erythropoietin; Granulocyte Colony-Stimulating Factor; Granulocyte-Macrophage Colony-Stimulating Factor; Histone Deacetylase Inhibitors; Humans; Immunosuppressive Agents; Interleukin-11; Iron Chelating Agents; Lenalidomide; Leukemia, Myelomonocytic, Chronic; Myelodysplastic Syndromes; Prognosis; Risk; Stem Cell Transplantation; Thalidomide; Triazoles | 2007 |
[Pathophysiology, diagnosis and treatment of anemia].
Topics: Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Azacitidine; Benzoates; Deferasirox; Diagnosis, Differential; Hematopoietic Stem Cell Transplantation; Humans; Iron Chelating Agents; Lenalidomide; Thalidomide; Triazoles | 2008 |
[Development trend in new therapeutic approaches for anemia].
Topics: Anemia; Benzoates; Clinical Trials as Topic; Darbepoetin alfa; Deferasirox; Erythropoietin; Hematinics; Humans; Iron Chelating Agents; Iron Overload; Lenalidomide; Myelodysplastic Syndromes; Neoplasms; Thalidomide; Triazoles | 2008 |
[MDS].
Topics: Azacitidine; Benzoates; Clinical Trials as Topic; Cytokines; Deferasirox; Drug Therapy, Combination; Humans; Lenalidomide; Myelodysplastic Syndromes; Thalidomide; Thrombopoietin; Treatment Outcome; Triazoles | 2012 |
[Myelodysplastic syndromes: treatment strategy up-to-date].
Topics: Antilymphocyte Serum; Azacitidine; Benzoates; Cyclosporine; Cytarabine; Deferasirox; Disease Progression; Drug Discovery; Drug Therapy, Combination; Erythropoietin; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Transplantation; Humans; Idarubicin; Immunosuppressive Agents; Iron Chelating Agents; Lenalidomide; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Quality of Life; Risk Assessment; Thalidomide; Triazoles | 2014 |
Current treatment strategies for measurable residual disease in patients with acute myeloid leukemia.
Topics: Aminopyridines; Aniline Compounds; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Agents, Immunological; Azacitidine; Cytogenetic Analysis; Decitabine; Enzyme Inhibitors; Flow Cytometry; Hematopoietic Stem Cell Transplantation; Humans; Hydrazines; Immunologic Factors; In Situ Hybridization, Fluorescence; Lenalidomide; Leukemia, Myeloid, Acute; Molecular Diagnostic Techniques; Neoplasm, Residual; Nivolumab; para-Aminobenzoates; Protein Kinase Inhibitors; Pyrazines; Pyrrolidines; Recombinant Fusion Proteins; Remission Induction; Transplantation, Homologous; Triazines; Triazoles | 2019 |
Novel Therapies for Relapsed or Refractory Diffuse Large B-Cell Lymphoma.
Topics: Adoptive Transfer; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Humans; Hydrazines; Immunoconjugates; Lenalidomide; Lymphoma, Large B-Cell, Diffuse; Triazoles | 2020 |
6 other study(ies) available for lenalidomide and triazoles
| Article | Year |
|---|---|
Myelodysplastic syndromes--many new drugs, little therapeutic progress.
Topics: Age Distribution; Antimetabolites, Antineoplastic; Antineoplastic Agents; Azacitidine; Benzoates; Deferasirox; Humans; Iron Chelating Agents; Lenalidomide; Myelodysplastic Syndromes; Survival Analysis; Thalidomide; Triazoles | 2010 |
Deferasirox treatment for myelodysplastic syndromes: "real-life" efficacy and safety in a single-institution patient population.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites; Azacitidine; Benzoates; Chelating Agents; Deferasirox; Drug Eruptions; Drug Evaluation; Drug Therapy, Combination; Female; Follow-Up Studies; Gastrointestinal Diseases; Hematinics; Humans; Iron Overload; Kidney Diseases; Lenalidomide; Male; Middle Aged; Myelodysplastic Syndromes; Retrospective Studies; Thalidomide; Treatment Outcome; Triazoles | 2012 |
Erythroid but not cytogenetic response in a case with 5q- syndrome: a delayed effect of lenalidomide or a consequence of deferasirox treatment?
Topics: Aged; Anemia, Macrocytic; Benzoates; Chromosome Deletion; Chromosomes, Human, Pair 5; Deferasirox; Erythroid Cells; Erythropoiesis; Female; Humans; Immunologic Factors; Lenalidomide; Myelodysplastic Syndromes; Thalidomide; Treatment Outcome; Triazoles | 2014 |
Immunomodulatory drugs target IKZF1-IRF4-MYC axis in primary effusion lymphoma in a cereblon-dependent manner and display synergistic cytotoxicity with BRD4 inhibitors.
Topics: Adaptor Proteins, Signal Transducing; Animals; Apoptosis; Azepines; Cell Cycle Proteins; Cell Line, Tumor; Cell Proliferation; Drug Synergism; Gene Knockdown Techniques; Humans; Ikaros Transcription Factor; Immunologic Factors; Interferon Regulatory Factors; Lenalidomide; Lymphoma, Primary Effusion; Mice; Nuclear Proteins; Peptide Hydrolases; Proto-Oncogene Proteins c-myc; Thalidomide; Transcription Factors; Triazoles; Ubiquitin-Protein Ligases; Xenograft Model Antitumor Assays | 2016 |
Ligand-mediated protein degradation reveals functional conservation among sequence variants of the CUL4-type E3 ligase substrate receptor cereblon.
Topics: Adaptor Proteins, Signal Transducing; Animals; Azepines; Cell Cycle Proteins; Cell Line, Tumor; Conserved Sequence; Cullin Proteins; Humans; Immunologic Factors; Lenalidomide; Ligands; Mice; Molecular Probes; Nuclear Proteins; Peptide Hydrolases; Proteasome Endopeptidase Complex; Proteolysis; T-Lymphocytes; Thalidomide; Transcription Factors; Triazoles; Ubiquitin; Ubiquitin-Protein Ligases | 2018 |
A Recurrent Activating Missense Mutation in Waldenström Macroglobulinemia Affects the DNA Binding of the ETS Transcription Factor SPI1 and Enhances Proliferation.
Topics: Animals; Azepines; B-Lymphocytes; Base Sequence; Binding Sites; Cell Line; Cell Proliferation; Gene Expression Regulation; Humans; Lenalidomide; Mice; Mutation, Missense; Myeloid Differentiation Factor 88; Nucleotide Motifs; Protein Binding; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-ets; Trans-Activators; Transcription Factors; Triazoles; Waldenstrom Macroglobulinemia | 2019 |